PeptidePedia The community reference

List of GLP-1 receptor agonists (revision 19)

Old revision·05:02, 28 Jul 2025·ListMakerLumi

This is an old revision of this page, as it stood at 05:02, 28 Jul 2025, saved by ListMakerLumi with the summary move the prose introduction above the table. It may differ substantially from the current revision, and any error it contains may since have been corrected.
List of GLP-1 receptor agonistsReference material
ScopeAgonists at the GLP-1 receptor, alone or with others
ExcludedDPP-4 inhibitors, which raise endogenous hormone
List infobox · conventions

This list enumerates agonists at the GLP-1 receptor, including those that also engage other receptors of the glucagon-secretin family. DPP-4 inhibitors are excluded: they raise endogenous incretin concentrations rather than agonising the receptor directly. See Dipeptidyl peptidase-4.[1]

Status is given as approved or investigational without specifying jurisdiction, since approval differs between countries. See Regulatory status by jurisdiction.[2]

Compounds appearing here are covered by their own articles where one exists. Inclusion is not an endorsement, and several entries are investigational compounds not approved anywhere.[3]

GLP-1 receptor agonists

[edit]
CompoundRouteIntervalStatus
ExenatideSubcutaneousTwice daily or weeklyApproved
LixisenatideSubcutaneousDailyApproved
LiraglutideSubcutaneousDailyApproved
DulaglutideSubcutaneousWeeklyApproved
SemaglutideSubcutaneousWeeklyApproved
Oral semaglutideOralDailyApproved
OrforglipronOralDailyInvestigational

The list spans three architectures: exendin-derived peptides, acylated GLP-1 analogues, an Fc fusion, and a non-peptide small molecule. See GLP-1 receptor agonist for how each solves the half-life problem.[1]

Multi-receptor agonists

[edit]
CompoundReceptorsStatus
TirzepatideGIP, GLP-1Approved
SurvodutideGlucagon, GLP-1Investigational
EfinopegdutideGlucagon, GLP-1Investigational
MazdutideGlucagon, GLP-1Investigational
RetatrutideGIP, GLP-1, glucagonInvestigational

These are treated at Dual incretin agonist and Triple agonist. Their receptor ratios are fixed by chemistry and are not comparable between publications, since reported potencies are assay-dependent.[1]

[edit]

Not agonists at the GLP-1 receptor, but discussed alongside them:

  • Cagrilintide — an amylin analogue, combined with semaglutide as CagriSema.
  • Insulin icodec — a weekly basal insulin; a different mechanism entirely.
  • DPP-4 inhibitors — raise endogenous incretin rather than agonising the receptor.

Compounds sold under any of these names outside licensed supply are research chemicals, not the approved products, and this wiki does not represent them as suitable for human use. See Research use only.[3]

See also

References

  1. ^ a b c Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
  2. ^ American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
  3. ^ a b United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
Categories: